Incorporating Health Technology Assessment (HTA) in Clinical Trials

February 22, 2017

IDDI organized a webinar on the current use and potential of Health Technology Assessment (HTA) as a component of clinical trials aimed at regulatory approval.
In this webinar, the speakers :

  • Provided an overview of the current use and potential of HTA as a component of clinical trials aimed at regulatory approval of novel agents in various medical fields
  • Introduced the general concept of HTA and cost-effectiveness in healthcare
  • Discussed how these aspects are becoming an important requirement for market access and how the relevant additional elements can be incorporated and collected in a phase III clinical trial
  • Illustrated the presentation with several examples, including clinical trials in which the authors have actively taken part as principal investigators and analysts
  • Made tentative conclusions about future directions and the impact of HTA data in the drug-development process.
TO ACCESS THE PRESENTATION OF THIS ON-DEMAND WEBINAR, PLEASE FILL OUT THE FORM BELOW

Incorporating Health Technology Assessment (HTA) in Clinical Trials

To access the presentation of this on-demand webinar, register to the right

IDDI organized a webinar on the current use and potential of HTA as a component of clinical trials aimed at regulatory approval.

Speakers

  • Everardo Saad, MD, Senior Medical Expert, IDDI
  • Oriana Ciani, PhD, Postdoctoral Research Fellow, University of Exeter Medical School; Research and Teaching Fellow, Centre for Research on Health and Social Care Management (CeRGAS), Bocconi University, Milan
  • Rod Taylor, MSc, PhD, Professor of Health Services Research, University of Exeter Medical School; Director, Exeter Clinical Trials Unit; Senior Investigator, National Institute for Health Research (NIHR), UK
Presentation of the Webinar : Incorporating Health Technology Assessment (HTA) in Clinical Trials

To access the presentation of this on-demand webinar, please fill out this form.

By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

I authorize IDDI to use my data to contact me for commercial purposes. More information
Powered by Atypic ®

IDDI